Holmium-166 Retrospective Collection of Real-World Data (RECORD)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Aalst, Belgium
- ASZ Aalst
-
Aalst, Belgium
- OLV Aalst
-
Bruxelles, Belgium
- CUB Hopital Erasme
-
-
-
-
-
Dresden, Germany
- Universitatsklinikum Carl Gustav Carus
-
Herford, Germany
- Klinikum Herford
-
Jena, Germany
- Universitatsklinikum Jena
-
Rostock, Germany
- Universitätsmedizin Rostock
-
-
-
-
-
Rome, Italy
- IFO IRCCS - Istituto Nazionale Tumori Regina Elena
-
-
-
-
-
Utrecht, Netherlands
- University Medical Center Utrecht
-
-
-
-
-
Porto, Portugal
- Instituto Português de Oncologia do Porto Francisco Gentil, EPE
-
-
-
-
-
Barcelona, Spain
- Hospital Universitari Germans Trias i Pujol
-
-
-
-
-
Basel, Switzerland
- Universitätsspital Basel
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient with diagnosis of primary liver tumor or metastases in the liver.
- Patients treated with QuiremScoutTM Holmium-166 Microspheres and/or QuiremSpheresTM Holmium-166 Microspheres from 15 July 2019 to 15 July 2021.
- Patient is ≥ 18 years.
- If required by national regulation, patient has understood and signed written informed consent to retrospective data collection.
Exclusion Criteria:
- Patients previously included in prospective interventional study with QuiremScoutTM Holmium-166 Microspheres and/or QuiremSpheresTM Holmium-166 Microspheres.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Frequency and Severity of Adverse Events
Time Frame: 30 months
|
The primary safety endpoint is defined in terms of incidence of adverse events CTCAE (Common Terminology Criteria for Adverse Events) grade ≥ 3, or any grade of a predefined list of events stemming from risk management of QuiremSpheresTM Holmium-166 Microspheres and QuiremScoutTM Holmium-166 Microspheres.
|
30 months
|
|
Progression Free Survival (PFS)
Time Frame: 30 months
|
Time from SIRT procedure until overall progression or death
|
30 months
|
|
Hepatic Progression Free Survival (HPFS)
Time Frame: 30 months
|
Time from SIRT procedure until progression in the liver or death
|
30 months
|
|
Overall survival (OS)
Time Frame: 30 months
|
Time from SIRT procedure until death from any cause
|
30 months
|
|
Tumor response in the liver
Time Frame: 3 months
|
Response as per routine practice following the guidelines for corresponding tumor type
|
3 months
|
|
Lung shunt prediction
Time Frame: 1 month
|
Lung shunt prediction will be evaluated by comparing the predicted and actual lung shunt, either in terms of percentage or absorbed dose
|
1 month
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Administered activity
Time Frame: 1 month
|
The technical performance of SIRT in term of administered activity in Becquerel (GBq or MBq) with QuiremSpheresTM Holmium-166 Microspheres.
|
1 month
|
|
Liver volume treated
Time Frame: 1 month
|
The technical performance of SIRT in term of liver volume treated in mL with QuiremSpheresTM Holmium-166 Microspheres.
|
1 month
|
|
SIRT treatment approach
Time Frame: 1 month
|
The technical performance of SIRT in term of treatment approach (selective, lobar, bi-lobar, whole liver) with QuiremSpheresTM Holmium-166 Microspheres.
|
1 month
|
|
Tumor absorbed dose
Time Frame: 1 month
|
The technical performance of SIRT in term of tumor absorbed dose in Gray (Gy) recorded from post-treatment imaging or based on injected activity and target volume with QuiremSpheresTM Holmium-166 Microspheres.
|
1 month
|
|
Normal liver absorbed dose
Time Frame: 1 month
|
The technical performance of SIRT in term of normal liver absorbed dose in Gray (Gy) recorded from post-treatment imaging or based on injected activity and target volume with QuiremSpheresTM Holmium-166 Microspheres.
|
1 month
|
|
The use of Q-SuiteTM in clinical practice
Time Frame: 1 month
|
The use of Q-SuiteTM in clinical practice will be recorded based on the software which is mentioned in the description of treatment or the presence of a Q-SuiteTM generated report in the patient's medical file.
|
1 month
|
|
Number of patients downstaged to liver resection or liver transplantation
Time Frame: 30 months
|
The number of patients downstaged to liver resection or liver transplantation will be reviewed based on the number of patients that underwent liver resection or liver transplantation after the SIRT procedure
|
30 months
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- T141E4
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.